Official Title
Current Practices on Antithrombotic Therapy in Hospitalised and Discharged Patients With COVID-19
Brief Summary

Evidence suggests coronavirus disease 2019 (COVID-19) is associated with an increased incidence of thromboembolic manifestations. Various guidelines on managing antithrombotics in COVID-19 either provided conflicting guidance or unclear recommendations for post-discharge thromboprophylaxis. The investigators aim to collect the current practices in India among physicians on antithrombotic therapy for hospitalised patients with COVID-19 and after discharge from the hospital.

Detailed Description

Immune dysregulation plays a crucial role in the development of severe coronavirus disease
2019 (COVID-19). The autopsy of lungs in deceased COVID-19 patients showed micro thrombosis
and inflammatory infiltrates similar to acute respiratory distress syndrome (ARDS). Reports
of increased incidence of arterial or venous thrombosis with COVID-19 made initial
recommendations regarding using higher doses of anticoagulation. The markers of thrombosis
like D-dimer, platelet count, fibrinogen are also increased in patients with COVID-19 along
with other inflammatory markers. The pathophysiology of coagulopathy of COVID-19 is still
under research. It is likely multi-factorial involving Inflammation, hypoxia, endothelial
dysfunction, direct viral cytopathic effect, platelets and complement activation, derangement
of the renin-angiotensin-aldosterone pathway.

From the inception of the pandemic, the physicians started using various antithrombotic with
higher than prophylactic doses to treat the prothrombotic state. In the absence of clear
guidance with conflicting evidence, there is considerable variation in the practices of
physicians managing COVID-19.

The investigators are planning for a nationwide multicentre cross-sectional survey on
understanding participating physicians practices on the choice of different antithrombotics
available in India as of August 2021.

The survey will have three sections: 1. Demographics 2. Antithrombotics in hospitalised
patients 3. Antithrombotics after discharge from the hospital

The investigators intend to involve 1000 physicians from different specialities with the help
of the steering committee.

Completed
COVID-19 Pneumonia
Thrombosis
COVID-19 Acute Respiratory Distress Syndrome
Severe Acute Respiratory Syndrome (SARS) Pneumonia

Behavioral: Current clinical practices of participating physicians

Current clinical practice of participating physicians on management of antithrombotics for COVID-19 during hospitalisation and post-discharge

Eligibility Criteria

Inclusion Criteria:

• Physicians involved in the management of adult hospitalised patients with COVID-19 in
India

Exclusion Criteria:

- Pediatricians

- Physicians involved in the out-patient management of COVID-19

- Refused to participate

Eligibility Gender
All
Eligibility Age
Minimum: 20 Years ~ Maximum: 70 Years
Countries
India
Locations

Reliance Hospital
Mumbai, Mumbai, Mahrastra, India

Prashant Nasa, MD EDICM, Principal Investigator
NMC Specialty Hospital, Dubai, UAE

NMC Specialty Hospital
NCT Number
Keywords
Anticoagulation in COVID-19
anticoagulants
SARS-CoV-2
Coronavirus disease 2019
Management of COVID-19
MeSH Terms
COVID-19
Pneumonia
Severe Acute Respiratory Syndrome
Respiratory Distress Syndrome
Respiratory Distress Syndrome, Newborn
Acute Lung Injury
Thrombosis
Syndrome